Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2008-08-01 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings Classification · 90% confidence The document is a short press release dated August 1, 2008, titled "Correction to the press release regarding sales milestone payments in Europe in connection with the new Licensing Agreement with ProStrakan." It corrects a specific financial figure (milestone payment amount) from a previous announcement. This is a specific, non-periodic corporate announcement that does not fit the definitions for 10-K, ER, IR, or DIV. It is not a management change (MANG), director dealing (DIRS), or a general regulatory filing (RNS). Since it is a specific announcement correcting prior information, and it is not a major event like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, specific corporate update, or potentially a general announcement about a licensing agreement detail, but RNS serves as the best fit for non-standard, specific corporate news releases that aren't covered by other codes.
2008-08-01 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a short press release dated August 1, 2008, titled "Correction of press release regarding sales level compensations in Europe in connection with the new license agreement with ProStrakan." It explicitly corrects a previously announced figure (19.9 MEUR instead of 29.9 MEUR) related to a licensing deal. This is a specific corporate announcement correcting prior information, not a full financial report (like 10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). Since it deals with a specific corporate transaction/financial detail correction, and there isn't a perfect fit for 'Correction Notice,' it falls best under the general 'Regulatory Filings' (RNS) as a miscellaneous, time-sensitive corporate update, or potentially 'Capital/Financing Update' (CAP) if the correction relates to a major financing event, but RNS is the safest general category for non-standard, short regulatory corrections. Given the options, RNS serves as the best general regulatory announcement category for this type of correction that isn't covered by more specific codes like DIV, SHA, or CAP.
2008-08-01 Swedish
M&A Activity 2008
M&A Activity Classification · 99% confidence The document is a press release dated July 31, 2008, announcing a significant change in a licensing agreement between Orexo and ProStrakan regarding the drug Rapinyl/Abstral, specifically involving the transfer of North American rights from Endo Pharmaceuticals back to Orexo and then to ProStrakan. This announcement details financial terms (milestones, royalties), development status (Phase III study completion), and strategic implications. This content is characteristic of a corporate action announcement related to financing, partnerships, or major business developments, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it details a major transaction involving rights and financing, the most appropriate category is Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were purely informational. Given the focus on expanding licensing rights and associated financial considerations (upfront payments, milestones, royalties), CAP is a strong fit, as it relates to capital structure/financing activities. However, since it is a general announcement about a business deal and not strictly about raising capital or debt issuance, and it doesn't fit the other specific categories well (like M&A (TAR) which is usually for takeovers/mergers), the general Regulatory Filings (RNS) category serves as the best fit for significant, non-standard corporate news releases that don't fit the other specific codes like DIV, SHA, or POS. Given the options, RNS is the most appropriate fallback for a major, non-standard corporate announcement of this nature, although CAP is plausible due to the financial terms discussed. I will select RNS as the general regulatory announcement category for significant corporate news that isn't a standard report or specific transaction type.
2008-07-31 Swedish
M&A Activity 2008
M&A Activity Classification · 99% confidence The document is a press release dated July 31, 2008, announcing an extension of a licensing agreement between Orexo and ProStrakan, which involves changes in partnership for North America and revised terms for Europe, including upfront payments, milestones, and royalty increases. This type of announcement details significant business transactions, financing terms, and strategic partnership changes related to drug development and commercialization rights. This fits best under 'Capital/Financing Update' (CAP) as it details financial commitments (\$29m in milestones, royalty changes) related to the licensing of a major asset, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. However, given the specific focus on financial terms, milestone payments, and the transfer of rights, CAP is the most precise fit among the provided options, as it relates directly to capital structure/financing arrangements for the asset. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific business/financing announcement.
2008-07-31 English
Regulatory Filings 2008
Regulatory Filings Classification · 96% confidence The document is a press release dated July 29, 2008, announcing that the FDA has accepted the registration application for a product called Sublinox™ for substantive review. This is an announcement regarding a regulatory step in the drug approval process, involving a pharmaceutical company (Orexo) and a regulatory body (FDA). It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a specific regulatory/legal update concerning product development and submission status. Since there is no specific code for 'Regulatory Submission Acceptance' or 'Product Development Update', and it concerns a legal/regulatory matter, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements that don't fit the other specific financial or corporate action codes. Given the context of a press release announcing a regulatory milestone, RNS is the most appropriate general classification.
2008-07-29 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is titled "Press meddelande" (Press release) dated July 29, 2008, announcing that the FDA has accepted the New Drug Application (NDA) for SublinoxTM for final review. This is a specific corporate announcement regarding regulatory progress for a product, not a comprehensive annual report (10-K), an interim report (IR), or a formal earnings release (ER). It details a significant step in the drug approval process, which is a type of corporate event announcement. Since there is no specific category for 'Regulatory Progress Announcement' or 'Drug Approval Update', and it is a formal, non-financial, non-governance announcement, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory/corporate news that doesn't fit the highly specific categories like DIRS, DIV, or CAP. Given the short length and nature as a news update, RNS is the most appropriate fit among the available options.
2008-07-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.